

**International Ovarian Cancer Research Consortium
and
International Symposium on Tumor Microenvironment**

Sunday, June 30

The Skirvin Hilton Hotel, 1 Park Avenue

7:30 AM – 8:30 AM *Registration & Breakfast*
Grand Ballroom Foyer, 2nd Floor

8:00 AM – 8:30 AM *Welcome Address*
James J Tomasek, PhD, Vice President for Research, University of Oklahoma Health Sciences Center
Robert S Mannel, MD, Director, Stephenson Cancer Center, OUHSC
Danny N Dhanasekaran, PhD, Director MTCRO-COBRE, Associate Director for Basic Research, Stephenson Cancer Center, OUHSC

COBRE Distinguished Speaker Plenary Lecture

8:30 AM – 9:05 AM *Lessons Learned from the Ovarian Cancer Moon Shot Program*
Anil K Sood, MD, University of Texas MD Anderson Cancer Center

Session I – Ovarian Cancer: New Perspectives

Session Chairs: Yong Sang Song, MD, PhD
Benjamin Tsang, PhD

9:05 AM – 9:25 AM *The inflammatory cytokine IL-6 promotes EMT in ovarian cancer cells via down-regulating glucose-dependent autophagy*
Ciro Isidoro, DSc, PhD, Università del Piemonte Orientale

9:25 AM – 9:45 AM *Regulation of ovarian cancer metastatic colonization by paracrine signals from the metastatic niche*
Anirban K Mitra, PhD, Indiana University School of Medicine-Bloomington


9:45 AM – 10:05 AM *Molecular characteristics of rare epithelial ovarian tumors and therapeutic implication*
Kwong K Wong, PhD, University of Texas MD Anderson Cancer Center

10:05 AM – 10:25 AM *Role of AMPK in Ovarian Cancer: A Metabolic and Immune Perspective*
Ramandeep Rattan, PhD, Henry Ford Hospital, Wayne State University

10:25 AM – 10:40 AM **Break**

Keynote Address

10:40 AM – 11:15 AM *Moving from Reactive to Proactive Medicine Through Data Science: Focus on Ovarian Cancer*
William S Dalton, MD, PhD, M2Gen, Moffitt Cancer Center



**International Ovarian Cancer Research Consortium
and
International Symposium on Tumor Microenvironment**

Session II – Precision Cancer Medicine: Data and Target Analysis

Session Chairs: Ciro Isidoro, DSc, MD

Barbara Vanderhyden, PhD

- 11:15 AM – 11:35 AM *Integrative analysis of clinical and multi-omics data for precision cancer medicine*
Yong Sang Song, MD, PhD, Seoul National University Hospital
- 11:35 AM – 11:55 AM *Diagnostic model based on EV metagenome data for ovarian cancer*
Taesung Park, PhD, Seoul National University
- 11:55 AM – 12:15 PM *MicroRNA Therapeutics in cancer*
Johji Inazawa, MD, PhD, Medical Research Institute, Tokyo Medical and Dental University
- 12:15 AM – 12:35 PM *Targeting lncRNAs in Ovarian Cancer*
Danny N Dhanasekaran, PhD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
- 12:35 PM – 1:30 PM **Lunch**

Keynote Address


- 1:30 PM – 2:05 PM *Epigenetic Approaches to Epithelial Ovarian Cancer*
Rugang Zhang, PhD, The Wistar Institute

Session III – Ovarian Cancer: Target Discovery

Session Chairs: Johji Inazawa, MD, PhD

Raghubir Athwal, PhD

- 2:05 PM – 2:25 PM *Monocytes and interferons as a therapeutic strategy for ovarian cancer*
Christina M Annunziata, MD, PhD, National Cancer Institute, National Institutes of Health
- 2:25 PM – 2:45 PM *Plasma Gelsolin: A Determinant of Chemosensitivity and A Prognostic Indicator of Stage 1 Disease and Residual Disease in Ovarian Cancer*
Benjamin K Tsang, PhD, University of Ottawa, Ottawa Hospital Research Institute
- 2:45 PM – 3:05 PM *Targetable Genetic Aberrations in Women's Cancer*
Pradeep Chaluvaly-Raghavan, PhD, Medical College of Wisconsin
- 3:05 PM – 3:25 PM *Targeting Ovarian Cancer: Identifying a Novel Toll Way*
Shrikant Anant, PhD, University of Kansas Medical Center
- 3:25 PM – 3:45 PM *Metformin abrogates age-associated ovarian fibrosis in women*
Barbara C Vanderhyden, PhD, University of Ottawa, Ottawa Hospital Research Institute



**International Ovarian Cancer Research Consortium
and
International Symposium on Tumor Microenvironment**

3:45 PM – 4:00 PM

Break

Session IV – Breast Cancer: Targeting Strategies

Session Chairs: Takemi Tanaka, PhD

Xin Zhang, PhD

4:00 PM – 4:20 PM

Engineering of On-Chip Organotypic Tumor Microenvironment Models to Study Cancer Progression

Mehdi Nikkah, PhD, Arizona State University

4:20 PM – 4:40 PM

NOS2 and COX2 as major drivers of poor outcome in ER- breast cancer. New therapeutic opportunities in a difficult disease

David A Wink, PhD, National Cancer Institute, National Institutes of Health

4:40 PM – 5:00 PM

Nitric oxide synthase inhibition and immunogenic cell death through RNA editing

Jenny C Chang, MD, Houston Methodist Hospital

5:00 PM – 5:20 PM


Role of DNPH1 in breast cancer

Ralf Janknecht, PhD, University of Oklahoma Health Sciences Center

5:20 PM – 5:40 PM

IL-6 induces epigenetic changes to promote incomplete angiogenesis in human breast tumors

Kapaettu Satyamoorthy, PhD, Manipal Academy of Higher Education



**International Ovarian Cancer Research Consortium
and
International Symposium on Tumor Microenvironment**

Monday, July 1

The Skirvin Hilton Hotel, 1 Park Avenue

7:30 AM – 8:30 AM *Registration & Breakfast*
Grand Ballroom Foyer, 2nd Floor

Keynote Address

8:00 AM – 8:35 AM *Implication of SIRT1 overexpression in growth and progression of human colon cancer cells and its inhibition by curcumin through covalent modification*
Young-Joon Surh, PhD, Seoul National University

Session V – Oncogenic Mechanisms: Newer Insights

Session Chairs: Lawrence Rothblum, PhD
John DiGiovanni, PhD

8:35 AM – 8:50 AM *Understanding the role of XRN2 in radiation resistance*
Julio C Morales, PhD, University of Oklahoma Health Sciences Center


8:50 AM – 9:10 AM *Cohesion Fatigue as a Source of Chromosome Instability in Cancer*
Gary J Gorbisky, PhD, Oklahoma Medical Research Foundation

9:10 AM – 9:30 AM *Roles and Mechanisms of Tetraspanins CD82 and CD151 in the Invasion and Metastasis of Solid Malignant Tumors*
Xin A Zhang, MD, PhD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center

9:30 AM – 9:50 AM *EphA2 Suppresses Hepatocarcinogenesis via Mitotic Arrest and Inhibition of ERK and Akt Activities*
Bingcheng Wang, PhD, Case Western Reserve University School of Medicine

9:50 AM – 10:10 AM *NRP-1 interacts with GIPC1 and SYX to activate p38 MAPK signaling and cancer stem cell survival*
Richard L Eckert, PhD, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine

10:10 AM – 10:25 AM **Break**



**International Ovarian Cancer Research Consortium
and
International Symposium on Tumor Microenvironment**

Session VI – Tumor Microenvironment: The Target Landscape

Session Chairs: Jie Wu, PhD

Priyabrata Mukherjee, PhD


- 10:25 AM – 10:45 AM *Adipose Stromal Cells, CXCL12, and Prostate Cancer Progression*
John DiGiovanni, PhD, University of Texas at Austin
- 10:45 AM – 11:05 AM *Investigating the complex roles of integrin alpha3-beta1 in carcinogenesis and modulation of the tumor microenvironment*
C Michael DiPersio, PhD, Albany Medical College
- 11:05 AM – 11:25 AM *Targeting CAF secretory autophagy for cancer therapy*
Sufi M Thomas, PhD, University of Kansas Medical Center
- 11:25 AM – 11:45 AM *The initiation of exosomal miRNA signaling in cancer cells*
Wei-Qun Ding, PhD, University of Oklahoma Health Sciences Center
- 11:45 AM – 12:05 PM *Roles of sex steroids and their receptors in inflammation and cancer metastasis*
Viroj Boonyaratanakornkit, PhD, Chulalongkorn University
- 12:05 PM – 12:20 PM *Analysis of migration associated treatment resistance in glioblastoma to identify novel therapeutics*
James D Battiste, MD, PhD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
- 12:20 PM – 1:00 PM **Lunch**

Session VII – Natural Compounds: Therapeutic Targeting

Session Chairs: Chin-Kun Wang, PhD

Chinthalapally V Rao, PhD

- 1:00 PM – 1:20 PM *Targeting Tumor Microenvironment: A holistic Approach for Prostate Cancer Chemoprevention by a Small Molecule Silibinin*
Rajesh Agarwal, PhD, University of Colorado Denver School of Pharmacy
- 1:20 PM – 1:40 PM *PARP-1 inhibitor INO-1001 (3-aminobenzamide) inhibits non-canonical parthanatos-like cell death in human leukaemia*
Marc F Diederich, PhD, Luxembourg & Seoul National University
- 1:40 PM – 2:00 PM *Intervention of Natural Bioactives on Ovarian Cancer*
Chin-Kun Wang, MD, PhD, Chung Shan Medical University
- 2:00 PM - 2:20 PM *Sulforaphane is a novel inhibitor of lipogenesis in prostate cancer*
Shivendra V Singh, PhD, UPMC Hillman Cancer Center, University of Pittsburgh
- 2:20 PM - 2:40 PM *Chinese herbal formula inhibits breast cancer cells in vitro by inducing apoptosis and attenuating inflammation*
Tewin Tencomnao, PhD, Chulalongkorn University



**International Ovarian Cancer Research Consortium
and
International Symposium on Tumor Microenvironment**

2:40 PM – 2:55 PM **Break**

Session VIII – Pancreatic Cancer: Biology and Therapy

Session Chairs: Min Li, PhD
Richard Eckert, PhD

- 2:55 PM – 3:15 PM *Wild-type KRAS exerts tumor suppression via cytoplasmic retention of YAP1*
Gloria H Su, PhD, Columbia University Irving Medical Center
- 3:15 PM – 3:35 PM *Develop a novel therapy for pancreatic cancer*
Min Li, PhD, University of Oklahoma Health Sciences Center
- 3:35 PM – 3:55 PM *The role of DCLK1 in immunosuppressive pancreatic cancer TME*
Dongfeng Qu, PhD, University of Oklahoma Health Sciences Center
- 3:55 PM – 4:15 PM *Targeting Mucins for Pancreatic Cancer Prevention/Treatment*
Chinthalapally V Rao, PhD, University of Oklahoma Health Sciences Center

Session IX – Cancer Discovery: Targets and Therapy

Session Chairs: Shivendra Singh, PhD
Rajesh Agarwal, PhD

- 4:15 PM – 4:35 PM *High Throughput Proteomics Approach to Human Disease*
Junmin Peng, PhD, St Jude Children's Research Hospital
- 4:35 PM – 4:55 PM *Identifying therapeutic targets in Cancer*
Priyabrata K Mukherjee, PhD, University of Oklahoma Health Sciences Center
- 4:55 PM – 5:15 PM *Targeted therapy and resistance mechanisms in RET oncogene-associated cancer*
Jie Wu, PhD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
- 5:15 PM – 5:30 PM *Optimization of an Antibody Therapy Against ELTD1 in a GBM Xenograft Model*
Rheal A Towner, PhD, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation
- 5:30 PM – 5:45 PM *miRNA signatures and response to platinum based chemotherapy in endometrial carcinoma, the search for predictive biomarkers of tumor response*
Katherine M Moxley, MD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
- 5:45 PM – 6:00 PM **Closing Remarks**
Johji Inazawa, MD, PhD
Yong Sang Song, MD, PhD
Young-Joon Surh, PhD
Ciro Isidoro, DSc, MD